Quantitative proteomic analysis of primary neurons reveals diverse changes in synaptic protein content in fmr1 knockout mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 40, 2008, Pages 15281-15286

  Liao, Lujian ^a   Sung, Kyu Park ^a   Xu, Tao ^a   Vanderklish, Peter ^a   Yates III, John R ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Fragile X syndrome; Mass spectrometry; Proteomics; Stable isotope labeling

Indexed keywords

AMINO ACID; FRAGILE X MENTAL RETARDATION PROTEIN; MESSENGER RNA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTISM; BRAIN CELL; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; EPILEPSY; IMMUNOBLOTTING; ISOTOPE LABELING; KNOCKOUT MOUSE; MATHEMATICAL MODEL; MOUSE; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEOMICS; QUANTITATIVE ANALYSIS; RNA TRANSPORT; SYNAPSE; UPREGULATION; WILD TYPE;

ANIMALS; CELLS, CULTURED; FRAGILE X MENTAL RETARDATION PROTEIN; ISOTOPE LABELING; MASS SPECTROMETRY; MICE; MICE, KNOCKOUT; NEURONS; PRESYNAPTIC TERMINALS; PROTEOME; PROTEOMICS; RNA, MESSENGER; SYNAPTOSOMES;

MUS;

EID: 55749088807     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0804678105     Document Type: Article

References (38)

1. de la Cruz FF (1985) Fragile X syndrome. Am J Ment Defic 90:119-123.
2. Hagerman RJ (2006) Fragile X-associated tremor/ataxia syndrome-an older face of the fragile X gene. J Dev Behav Pediatr 27:63-74.
3. Di Bonaventura C, et al. (2006) Status epilepticus in a patient with fragile X syndrome: Electro-clinical features and peri-ictal neuroimaging. Epileptic Disord 8:195-199.
4. Irwin SA, Galvez R, Greenough WT (2000) Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex 10:1038-1044.
5. Grossman AW, Aldridge GM, Weiler IJ, Greenough WT (2006) Local protein synthesis and spine morphogenesis: Fragile X syndrome and beyond. J Neurosci 26:7151-7155.
6. Koekkoek SK, et al. (2005) Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome. Neuron 47:339-352.
7. O'Donnell WT, Warren ST (2002) A decade of molecular studies of fragile X syndrome. Annu Rev Neurosci 25:315-338.
8. Bear MF, Huber KM, Warren ST (2004) The mGluR theory of fragile X mental retardation. Trends Neurosci 27:370-377.
9. Vanderklish PW, Edelman GM (2005) Differential translation and fragile X syndrome. Genes Brain Behav 4:360-384.
10. Darnell JC, et al. (2001) Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell 107:489-499.
11. Miyashiro KY, et al. (2003) RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron 37:417-431.
12. Brown V, et al. (2001) Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 107:477-487.
13. Washburn MP, Wolters D, Yates JR, 3rd (2001) Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 19:242-247.
14. Mann M (2006) Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol 7:952-958.
15. Bose R, et al. (2006) Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc Natl Acad Sci USA 103:9773-9778.
16. Blagoev B, et al. (2003) A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling. Nat Biotechnol 21:315-318.
17. Park KS, Mohapatra DP, Misonou H, Trimmer JS (2006) Graded regulation of the Kv2.1 potassium channel by variable phosphorylation. Science 313:976-979.
18. OngSE, et al. (2002) Stable isotope labeling byaminoacids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 1:376-386.
19. Carlin RK, Bartelt DC, Siekevitz P (1983) Identification of fodrin as a major calmodulin-binding protein in postsynaptic density preparations. J Cell Biol 96:443-448.
20. McClatchy DB, Dong MQ, Wu CC, Venable JD, Yates JR, 3rd (2007) (15)N metabolic labeling of mammalian tissue with slow protein turnover. J Proteome Res 6:2005-2010.
21. Washbourne P, Bennett JE, McAllister AK (2002) Rapid recruitment of NMDA receptor transport packets to nascent synapses. Nat Neurosci 5:751-759.
22. D'Agata V, et al. (2002) Gene expression profiles in a transgenic animal model of fragile X syndrome. Neurobiol Dis 10:211-218.
23. Zeeberg BR, et al. (2003) GoMiner: A resource for biological interpretation of genomic and proteomic data. Genome Biol 4:R28.
24. Ong SE, Foster LJ, Mann M (2003) Mass spectrometric-based approaches in quantitative proteomics. Methods 29:124-130.
25. Pratt JM, et al. (2002) Dynamics of protein turnover, amissing dimension in proteomics. Mol Cell Proteomics 1:579-591.
26. Doherty MK, Whitehead C, McCormack H, Gaskell SJ, Beynon RJ (2005) Proteome dynamics in complex organisms: Using stable isotopes to monitor individual protein turnover rates. Proteomics 5:522-533.
27. Sirotkin H, et al. (1997) Identification of a new human catenin gene family member (ARVCF) from the region deleted in velo-cardio-facial syndrome. Genomics 41:75-83.
28. Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D (1993) Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 361:453-457.
29. Shin CY, Kundel M, Wells DG (2004) Rapid, activity-induced increase in tissue plasminogen activator is mediated by metabotropic glutamate receptor-dependent mRNA translation. J Neurosci 24:9425-9433.
30. Calabresi P, et al. (2000) Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory. Eur J Neurosci 12:1002-1012.
31. Heaton JH, Dlakic WM, Dlakic M, Gelehrter TD (2001) Identification and cDNA cloning of a novel RNA-binding protein that interacts with the cyclic nucleotide-responsive sequence in the Type 1 plasminogen activator inhibitor mRNA. J Biol Chem 276:3341-3347.
32. Goodier JL, Zhang L, Vetter MR, Kazazian HH, Jr (2007) LINE-1 ORF1 protein localizes in stress granules with other RNA-binding proteins, including components of RNA interference RNA-induced silencing complex. Mol Cell Biol 27:6469-6483.
33. Kates WR, et al. (2007) Comparing phenotypes in patients with idiopathic autism to patients with velocardiofacial syndrome (22q11 DS) with and without autism. Am J Med Genet A 143:2642-2650.
34. Laumonnier F, et al. (2006) Association of a functional deficit of the BKCa channel, a synaptic regulator of neuronal excitability, with autism and mental retardation. Am J Psychiatry 163:1622-1629.
35. Hu H, et al. (2001) Presynaptic Ca2+-activated K+ channels in glutamatergic hippocampal terminals and their role in spike repolarization and regulation of transmitter release. J Neurosci 21:9585-9597.
36. Jensen BS (2002) BMS-204352: A potassium channel opener developed for the treatment of stroke. CNS Drug Rev 8:353-360.
37. Goslin K, Banker G (1989) Experimental observations on the development of polarity by hippocampal neurons in culture. J Cell Biol 108:1507-1516.
38. Spellman DS, Deinhardt K, Darie CC, Chao MV, Neubert TA (2008) Stable isotopic labeling by amino acids in cultured primary neurons: Application to brain-derived neurotrophic factor-dependent phosphotyrosine-associated signaling. Mol Cell Proteom 7:1067-1076.